Cargando…

Tildrakizumab in moderate‐to‐severe plaque psoriasis: A multicenter, retrospective, real‐life study

New biologic agents targeting interleukin (IL)23/T‐helper17 axis, such as tildrakizumab, have been developed for the treatment of plaque psoriasis. To analyze the efficacy and safety of tildrakizumab in a real life setting of patients affected by moderate‐to‐severe psoriasis over a 28‐week treatment...

Descripción completa

Detalles Bibliográficos
Autores principales:	Caldarola, Giacomo, Galluzzo, Marco, Bernardini, Nicoletta, Calabrese, Laura, Grimaldi, Marta, Moretta, Gaia, Pagnanelli, Gianluca, Shumak, Ruslana Gaeta, Talamonti, Marina, Tofani, Lorenzo, Pallotta, Sabatino, Peris, Ketty, Potenza, Concetta, De Simone, Clara, Campione, Elena
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9287013/ https://www.ncbi.nlm.nih.gov/pubmed/35384168 http://dx.doi.org/10.1111/dth.15488

Ejemplares similares

Efficacy of Tildrakizumab for the Treatment of Difficult-to-Treat Areas: Scalp, Nail, Palmoplantar and Genital Psoriasis
por: Galluzzo, Marco, et al.
Publicado: (2022)

A Real-Life Study on the Use of Tildrakizumab in Psoriatic Patients
por: Campione, Elena, et al.
Publicado: (2023)

Long term efficacy, safety, and tolerability of tildrakizumab in epileptic patient with psoriasis and eczema
por: Bernardini, Nicoletta, et al.
Publicado: (2022)

Effectiveness of risankizumab in the treatment of palmoplantar psoriasis: a 52-week Italian real-life experience
por: Caldarola, Giacomo, et al.
Publicado: (2023)

Risankizumab for the treatment of moderate‐to‐severe psoriasis: A multicenter, retrospective, 1 year real‐life study
por: Caldarola, Giacomo, et al.
Publicado: (2022)

Treatment of moderate-to-severe plaque psoriasis with tildrakizumab in the real-life setting
por: Burlando, Martina, et al.
Publicado: (2021)

Use of Guselkumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A 1 Year Real-Life Study
por: Galluzzo, Marco, et al.
Publicado: (2020)

Profile of tildrakizumab-asmn in the treatment of moderate-to-severe plaque psoriasis: evidence to date
por: Beck, Kristen M, et al.
Publicado: (2018)

Erratum: Treatment of moderate-to-severe plaque psoriasis with tildrakizumab in the real-life setting
Publicado: (2021)

Tildrakizumab: Successful Response in Two Patients With Psoriatic Arthritis
por: Buononato, Dario, et al.
Publicado: (2022)

Optimizing care for psoriatic patients requiring systemic therapies: how will COVID-19 disease transform risk perceptions?
por: Talamonti, M., et al.
Publicado: (2020)

Erythrodermic psoriasis improved by Tildrakizumab
por: Trevisan, Giampaolo, et al.
Publicado: (2022)

Tildrakizumab: An Evidence-Based Review of Its Use in the Treatment of Moderate-to-Severe Chronic Plaque Psoriasis
por: Näslund-Koch, Charlotte, et al.
Publicado: (2020)

From In Silico Simulation between TGF-β Receptors and Quercetin to Clinical Insight of a Medical Device Containing Allium cepa: Its Efficacy and Tolerability on Post-Surgical Scars
por: Cosio, Terenzio, et al.
Publicado: (2023)

Tildrakizumab in the treatment of psoriasis – literature review
por: Banaszczyk, Katarzyna
Publicado: (2019)

Tildrakizumab ineffective in generalized granuloma annulare
por: Song, Eingun James
Publicado: (2020)

Spotlight on brodalumab in the treatment of plaque psoriasis: the evidence to date
por: Galluzzo, M, et al.
Publicado: (2019)

Letter in response to the case report: “Recalcitrant generalized granuloma annulare treated successfully with dupilumab”
por: Paganini, Claudia, et al.
Publicado: (2023)

The Budget Impact of Introducing Tildrakizumab to a United States Health Plan for Managing Moderate-to-Severe Plaque Psoriasis
por: Carrico, Justin, et al.
Publicado: (2020)

Clearance of head and neck involvement in plaque psoriasis with tildrakizumab treatment in the phase 3 reSURFACE 1 study
por: Menter, M.A., et al.
Publicado: (2020)

A Retrospective Real-World Study of the Effectiveness and Tolerability of Tildrakizumab in UK Adults with Moderate-to-Severe Chronic Plaque Psoriasis
por: Becher, Gabrielle, et al.
Publicado: (2022)

Tildrakizumab in the treatment of psoriasis: latest evidence and place in therapy
por: Pithadia, Deeti J., et al.
Publicado: (2019)

Assessment of the effects of immunogenicity on the pharmacokinetics, efficacy and safety of tildrakizumab
por: Kimball, A.B., et al.
Publicado: (2019)

Tildrakizumab: A new therapeutic option for erythrodermic psoriasis?
por: Megna, Matteo, et al.
Publicado: (2021)

Guselkumab for the treatment of severe plaque psoriasis in a schizophrenia patient
por: Bernardini, Nicoletta, et al.
Publicado: (2022)

Clinico-dermoscopic features of alopecia areata in patients with psoriasis
por: Tassone, Francesco, et al.
Publicado: (2018)

Efficacy and Safety of Tildrakizumab in a Patient with Chronic HBV Infection
por: Potestio, Luca, et al.
Publicado: (2023)

Real‐life effectiveness of tildrakizumab in chronic plaque psoriasis: A 52‐week multicentre retrospective study—IL PSO (Italian landscape psoriasis)
por: Narcisi, Alessandra, et al.
Publicado: (2022)

Real‐world effectiveness and safety of tildrakizumab in long‐term treatment of plaque psoriasis: Results from the non‐interventional, prospective, multicentre study TILOT
por: Tsianakas, Athanasios, et al.
Publicado: (2022)

A Case of Concurrent Psoriasis and Hidradenitis Suppurativa Successfully Treated with Tildrakizumab
por: Damsin, Thomas
Publicado: (2023)

Successful treatment of acrodermatitis continua of Hallopeau with tildrakizumab: A case report
por: Nguyen, Alex, et al.
Publicado: (2023)

Efficacy and safety of tildrakizumab for plaque psoriasis with continuous dosing, treatment interruption, dose adjustments and switching from etanercept: results from phase III studies
por: Kimball, A.B., et al.
Publicado: (2019)

Eruptive lentiginosis in resolving plaque psoriasis during treatment with risankizumab
por: Palmisano, Gerardo, et al.
Publicado: (2023)

Treatment of psoriasis with etanercept in immunocompromised patients: Two case reports
por: De Simone, Clara, et al.
Publicado: (2016)

Efficacy and safety of tildrakizumab 100 mg for plaque psoriasis in patients randomized to treatment continuation vs treatment withdrawal with retreatment upon relapse in reSURFACE 1
por: Cantrell, W., et al.
Publicado: (2021)

Efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 64‐week phase 3 study (reSURFACE 1)
por: Igarashi, Atsuyuki, et al.
Publicado: (2021)

Importance of genotyping patients for HLA-C*06:02: it provides not only pharmacogenetics implication in response to biologics drugs but also drug survival and drug-related costs information
por: Talamonti, Marina, et al.
Publicado: (2020)

A Systematic Literature Review and Bucher Indirect Comparison: Tildrakizumab versus Guselkumab
por: Du Jardin, Kristian Garn, et al.
Publicado: (2020)

Guselkumab, Risankizumab, and Tildrakizumab in the Management of Psoriasis: A Review of the Real-World Evidence
por: Ruggiero, Angelo, et al.
Publicado: (2022)

Recalcitrant Ulcerative Pyoderma Gangrenosum of the Leg Responsive to Tildrakizumab: A Case Report
por: Leow, Liang Joo, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_i28luagk7vtm2hdsegbb92ek9u